Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Merck & Co.'s Solid Growth Turbo-Charged By Lagevrio For COVID-19

28 Apr 2022

• By Jessica Merrill

motor boat — Lagevrio powered Merck & Co.'s first quarter sales • Source: Alamy (Alamy Stock Photo)

Related Content

Pfizer Is Changed ‘Forever’ By COVID-19; Revenue Forecast Hits Triple Digits

08 Feb 2022

Merck’s $11.5bn Acceleron Buy Partially Fills Future Keytruda Revenue Gap

30 Sep 2021

Merck & Co Maps Out Route To $10bn Cardiovascular Franchise

06 Apr 2022

The Next Big Patent Cliff Is Coming, And Time Is Running Out To Pad The Fall

04 Apr 2022

Related Companies

Merck & Co., Inc.

Pfizer Inc.

Acceleron Pharma, Inc.

Additional Topics

Sales & Earnings M & A Coronavirus COVID-19 Business Strategies BioPharmaceutical

More from Earnings

More from Business

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window

Copyright © 2025 Pharma Intelligence UK Limited (Citeline), a Norstella company Pharma Intelligence UK Limited is a company registered in England and Wales with company number 13787459 whose registered.